XSHG
600421
Market cap7mUSD
Jun 22, Last price
0.24CNY
Name
Hubei Huarong Holding Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hubei Huarong Holding Co.,Ltd. is a pharmaceutical enterprise primarily engaged in the manufacturing and distribution of medicinal products across China. Its core pharmaceutical offerings notably feature Gucining Capsules and Huoxue Tongmai Capsules. Beyond its traditional drug production, the company also actively develops biological products, novel pharmaceuticals, environmental protection solutions, and agricultural goods, along with the technologies supporting these areas. The organization was formerly known as Hubei Yangfan Holding Co., Ltd. before officially adopting its current name, Hubei Huarong Holding Co.,Ltd., in November 2020. Established in 1997, the firm maintains its main operational base in Wuhan, China.
Key people
Chaoyang Jin
Vice Chairman of the Board · since 2019
Caibing Wen
Chief Financial Officer · since 2025
Gang Wang
Deputy General Manager · since 2024
Qu Shuai
General Manager, Secretary of the Board · since 2025
Xinghua Fang
Director · since 2025
Dandan Han
Director · since 2019
Zhuo Zhan
Director · since 2026
Lianghui Zhou
Chairman of the Board · since 2025
Yu Cai
Independent Director · since 2024
Junxun Dai
Independent Director · since 2025
Canlin Lu
Independent Director · since 2025
Yang Yu
Independent Director · since 2026
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||